Ovarian Auto-grafting
Ovarian Auto-grafting - Related Videos
09:25
Transplantation Into the Mouse Ovarian Fat Pad
0 Views •
Cited by 7 •
2016
We describe an ovarian fad pad transplantation assay suitable for studies of normal and transformed epithelia of the female reproductive tract. The mouse fat pad allows transplantation of large tissue fragments, is easily accessible for surgery and imaging, and provides the most favorable native environment for tissues of Müllerian origin.
10:35
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
0 Views •
Cited by 18 •
2010
To study in vivo tumor growth and tumor microenvironment, we used a syngeneic and orthotopic mouse model of ovarian cancer in immunocompetent animals. We transduced a mouse tumor cell line (MOV1) with Katushka fluorescent protein (MOV1KAT) and here we show its orthotopic implantation in ovary and in vivo imaging.
10:58
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
0 Views •
Cited by 15 •
2016
Ovarian cancer metastasis is characterized by numerous diffuse intra-peritoneal lesions, such that accurate visual quantitation of tumor burden is challenging. Herein we describe a method for in situ and ex vivo quantitation of metastatic tumor burden using red fluorescent protein (RFP)-labeled tumor cells and optical imaging.
04:35
Obtaining Primary Ovarian Cancer Cells from Solid Specimens: A Method to Culture Epithelial Ovarian Cancer Cells from Ovarian Tumor Specimens
0 Views •
2023
In this video, we describe a method for isolating and characterizing primary ovarian cancer cells from solid ovarian tumor tissue specimens. The epithelial cancer cells obtained using this protocol are suitable for understanding the processes that may lead to ovarian cancer initiation and development.
07:37
Mouse Models for Graft Arteriosclerosis
0 Views •
Cited by 17 •
2013
We describe protocols for our mouse graft arteriosclerois (GA) models which involve interposition of a mouse vessel segment into a recipient of the same inbred strain. By backcrossing additional genetic changes into the vessel donor, the model can assess the effect of specific genes on GA.
FAQs
Function depends first on revascularization, meaning the graft must re-establish a blood supply after transplantation. Surviving follicles can then resume activity, produce ovarian hormones, and potentially support oocyte maturation. This sequence links early graft survival with later endocrine recovery and possible fertility-related outcomes.
The transplanted tissue must tolerate the interval before revascularization is restored. Ischemic injury can reduce the amount of viable ovarian tissue and limit the follicles available for later activity. Consequently, the extent of this injury helps determine whether the graft can recover endocrine function or contribute to reproductive potential.
Outcomes vary with tissue quality, the graft site, the degree of ischemic injury, the patient’s age, and her remaining ovarian reserve. These variables affect how much tissue survives, how effectively follicles resume activity, and whether hormone production or potential oocyte maturation can be restored after transplantation.
The process begins with ovarian tissue removal, followed by cryopreservation when the tissue is stored for later use. At an appropriate later stage, the preserved tissue is grafted back into the patient. The transplanted tissue must then revascularize and re-establish follicular activity for functional recovery to occur.
Ovarian autografting is used primarily when a patient faces treatment or a condition that threatens ovarian function. It is particularly relevant to fertility preservation before gonadotoxic cancer treatment, because ovarian tissue can be removed and preserved before exposure to an intervention that may damage the patient’s ovarian reserve.
A successful graft may restore endocrine activity by enabling surviving follicles to produce hormones. It may also support oocyte maturation and potential fertility, although outcomes are not uniform. Tissue quality, graft location, ischemic injury, age, and ovarian reserve all influence whether hormonal or reproductive benefits are achieved.